Stocks
Sino Biopharmaceutical Limited Financial Statements (SBMFF) |
||||||||||
| Sino Biopharmaceutical Limitedsmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 31.12.2019 | 31.12.2020 | 31.12.2021 | 31.12.2022 | 31.12.2023 | 31.12.2023 | ||||
| Currency | CNY | CNY | CNY | CNY | CNY | CNY | ||||
| Revenue, bln rub | ? | 24 234 | 23 647 | 26 861 | 28 780 | 26 199 | ||||
| Operating Income, bln rub | 5 808 | 4 888 | 18 860 | 6 690 | 5 439 | |||||
| EBITDA, bln rub | ? | 7 366 | 6 991 | 19 874 | 6 691 | 6 979 | ||||
| Net profit, bln rub | ? | 2 762 | 2 771 | 14 608 | 2 544 | 2 332 | ||||
| OCF, bln rub | ? | 5 325 | 5 325 | 5 366 | 6 265 | 6 066 | ||||
| CAPEX, bln rub | ? | 1 734 | 1 859 | 1 894 | 1 706 | 1 704 | ||||
| FCF, bln rub | ? | 3 591 | 3 466 | 3 472 | 4 560 | 4 362 | ||||
| Dividend payout, bln rub | 819.7 | 1 187 | 938.5 | 1 268 | 632.7 | |||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |||||
| Dividend payout ratio, % | 29.7% | 42.8% | 6.42% | 49.8% | 27.1% | |||||
| OPEX, bln rub | 14 217 | 14 161 | 17 186 | 16 949 | 15 916 | |||||
| Cost of production, bln rub | 4 926 | 5 182 | 5 332 | 5 796 | 4 990 | |||||
| R&D, bln rub | 2 399 | 2 627 | 3 747 | 4 333 | 4 403 | |||||
| Interest expenses, bln rub | 230.0 | 323.4 | 308.6 | 439.1 | 495.2 | |||||
| Assets, bln rub | 58 299 | 47 210 | 60 543 | 64 064 | 63 605 | 63 605 | ||||
| Net Assets, bln rub | ? | 31 112 | 16 747 | 30 291 | 29 747 | 30 474 | 30 474 | |||
| Debt, bln rub | 8 616 | 14 210 | 12 118 | 13 982 | 12 580 | 12 580 | ||||
| Cash, bln rub | 19 106 | 16 432 | 15 794 | 16 922 | 14 118 | 14 118 | ||||
| Net debt, bln rub | -10 490 | -2 222 | -3 677 | -2 940 | -1 538 | -1 538 | ||||
| Ordinary share price, rub | 1.47 | 0.980 | 0.665 | 0.585 | 0.416 | |||||
| Number of ordinary shares, mln | 18 811 | 18 800 | 18 769 | 18 622 | 18 529 | |||||
| Market cap, bln rub | 27 652 | 18 424 | 12 481 | 10 894 | 7 708 | 0 | ||||
| EV, bln rub | ? | 17 163 | 16 202 | 8 805 | 7 954 | 6 170 | -1 538 | |||
| Book value, bln rub | 8 280 | 14 500 | 28 579 | 27 833 | 29 546 | 29 546 | ||||
| EPS, rub | ? | 0.15 | 0.15 | 0.78 | 0.14 | 0.13 | ||||
| FCF/share, rub | 0.19 | 0.18 | 0.19 | 0.24 | 0.24 | |||||
| BV/share, rub | 0.44 | 0.77 | 1.52 | 1.49 | 1.59 | |||||
| EBITDA margin, % | ? | 30.4% | 29.6% | 74.0% | 23.2% | 26.6% | ||||
| Net margin, % | ? | 11.4% | 11.7% | 54.4% | 8.84% | 8.90% | ||||
| FCF yield, % | ? | 13.0% | 18.8% | 27.8% | 41.9% | 56.6% | ||||
| ROE, % | ? | 8.88% | 16.5% | 48.2% | 8.55% | 7.65% | 0 | |||
| ROA, % | ? | 4.74% | 5.87% | 24.1% | 3.97% | 3.67% | 0 | |||
| P/E | ? | 10.0 | 6.65 | 0.85 | 4.28 | 3.31 | ||||
| P/FCF | 7.70 | 5.32 | 3.59 | 2.39 | 1.77 | |||||
| P/S | ? | 1.14 | 0.78 | 0.46 | 0.38 | 0.29 | ||||
| P/BV | ? | 3.34 | 1.27 | 0.44 | 0.39 | 0.26 | 0 | |||
| EV/EBITDA | ? | 2.33 | 2.32 | 0.44 | 1.19 | 0.88 | ||||
| Debt/EBITDA | -1.42 | -0.32 | -0.18 | -0.44 | -0.22 | |||||
| R&D/CAPEX, % | 138.3% | 141.3% | 197.8% | 254.0% | 258.4% | |||||
| CAPEX/Revenue, % | 7.16% | 7.86% | 7.05% | 5.93% | 6.50% | |||||
| Sino Biopharmaceutical Limited shareholders | ||||||||||
